Biotechnology
Group at a Glance
- 27 members
- 26 members have doctorate or medical degrees
- Members' backgrounds include: Biochemistry, Bioengineering, Biology, Epidemiology, Genetics, Medical Biophysics, Neuroscience, Oncology, Physical Chemistry, Psychobiology, and Toxicology
What Matters to Our Clients
Client Base
We measure our value on a simple metric: our clients stay with us for many years. Often remaining with us after being acquired, they like the fact that we have a remarkable degree of stability among our people. Our clients can rely on the consistency of a solid team to keep pace with their growth.
Working with world leaders in industry and academia, we also represent start-ups and non-profits in the biotech and life sciences space. Our experienced understanding of the issues at stake means that we bring realistic solutions to the table.
Team Approach
Efficient and cost-effective client service is a core firm value. In our Biotechnology Group, that value means working with our Chemical & Materials Technologies Group and our Pharmaceutical Group when their specialized expertise will benefit a client’s project. Our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.
Technical Depth and Breadth
When it comes to advanced scientific degrees, we field the largest biotechnology group in New England. Aggressively recruiting people who are closest to advancing technology, we quickly grasp the nuances of complex biotechnology matters.
Our clients appreciate the easy way we communicate with their inventors and scientists on the fine distinctions of a particular innovation, and with their business executives on issues that impact the future commercial value of their technology.
The services we provide include: IP strategic planning; patent and trademark acquisition and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; interferences; and competitor analysis.
Areas of Expertise
Examples of our group's areas of expertise include:
- Detection systems
- Data mining and analysis
- Diagnostic assays
- Molecular modeling
- Pattern recognition
- Cloning & transgenic technologies
- Gene discovery
- Gene therapy
- Pharmacogenomics
- Population genetics
- Proteomics
- Quantitative genetics
- Allergy
- Arthritis
- Bone & mineral diseases
- Cancer
- Cardiovascular
- Dermatology
- Developmental biology
- Diabetes
- Endocrinology, metabolism & lipids
- Gastroenterology
- Hematology
- Immunology
- Infectious disease
- Neurology
- Obstetrics & gynecology
- Ophthalmology
- Orthopedics
- Psychiatry
- Pulmonary
- Renal
- Rheumatology
- Tissue engineering
- Toxicology
- Transplantation
- Vaccines
- Bacteriology
- Mycology
- Parasitology
- Probiotics
- Virology
- Computational neuroscience
- Neuroanatomy
- Neurodegenerative diseases
- Neurophysiology
- Phychobiology
- Psychopharmacology
- Nucleic acids
- Polysaccharides
- Proteins
- Computational biology
- Synthetic biology
- Ablynx
- Boston College
- Dana Farber Cancer Institute
- Dyax Corporation
- GlaxoSmithKline
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Partners Healthcare
- Progenics Pharmaceuticals Inc.
- Shire Pharmaceuticals
- University of Vermont
July 2010 - Risks of False Marking: Reducing Your Exposure
July 2010 - Bilski decision leaves many questions unanswered for TTOs
June 2010 - Bilski ruling from US Supreme Court
July 2, 2010 - Industry Groups, Practitioners React To High Court Decision on Method Patents
July 7, 2010 - A Wolf Greenfield Webinar: Forecasting the Future of Method Patents Post-Bilski — archived replay of webinar now available
June 28, 2010 - CLIENT ALERT— Supreme Court Leaves Door Open to Business Method Patents
June 17, 2010 - WOLF GREENFIELD SEMINAR: Strategically Building and Monetizing a Patent Portfolio - replay now available
June 2, 2010 - Wolf Greenfield’s litigation team secured summary judgment of no patent infringement for our client The Jackson Laboratory
April 16, 2010 - Patent Applications Must Have Separate Written Description
April 14, 2010 - CLIENT ALERT— Federal Circuit Decision Reaffirms Separate Written Description Requirement
April 2, 2010 - Practitioners See Little Change From Ariad Decision, Caution Inventors on When to File
April 2, 2010 - CLIENT ALERT— The New Biosimilar Pathway: Biologics Price Competition and Innovation Act
March 31, 2010 - Gene Patent Ruling Could Shake Up Biotech
March 31, 2010 - Look, You Wanna Invent? You'd Better WRITE IT DOWN
February 26, 2010 - Wolf Greenfield wins key claim construction ruling for The Jackson Laboratory
February 19, 2010 - More Organizations Ask PTO to Recalculate Term Adjustments
January 2010 - Michael Siekman interviewed by IP Lawcast
January 13, 2010 - CLIENT ALERT— Federal Circuit Affirms Decision Finding USPTO Miscalculates Patent Term Adjustment
November 18, 2009 - WOLF GREENFIELD SEMINAR: Biotechnology Patent Drafting: New Strategies for New Times- replay now available
October 15, 2009 - CLIENT ALERT — USPTO Rescinds Controversial Rules Restricting Patent Applications
October 2009 - Court Case on Patent Delays Holds Appeal for Industry
October 10, 2009 - Federal Circuit Confirms Diagnostic and Therapeutic Methods Can be Patentable Subject Matter
September 25, 2009 - Lack of timing awareness can mean missed revenue
September 24, 2009 - CLIENT ALERT — Federal Circuit Confirms Diagnostic and Therapeutic Methods Can be Patentable Subject Matter
May 14, 2009 - Our clients Cambridge NanoTech and E Ink named winners of SBANE’s New England Innovation Awards, and our client Formulatrix named as finalist
April 10, 2009 - Gilead's Hypertension Drug Darusentan Will Likely Receive Patent
March 25, 2009 - CLIENT ALERT — Federal Circuit Decision on Controversial PTO Rules
February 2009 - Maximizing Intellectual Property Value in Tough Economic Times- Seminar replay now available
November 12, 2008 - Navigating Technology Collaborations and Joint Ventures—Wolf Greenfield seminar
August 2008 - Wolf Greenfield wins three more years of patent protection for Shire Pharmaceuticals' ELAPRASE treatment
June 6, 2008 - Biotech, IT Stalemate Puts Breaks on IP Reform Law
June, 2008 - Stem Cell Gold Rush
April 11, 2008 - "Patent Issues & Potential Problems" – Invention to Venture Conference / University of Vermont
February 7, 2008 - An Entrepreneur's Guide to the Intellectual Property Galaxy
January 9, 2008 - Wolf Greenfield, Boston, Names Two New Shareholders - Boston Intellectual Property Law Firm Promotes Teja, Trevisan
August 8, 2007 - Wolf Greenfield Names Van Amsterdam to Head Biotech Law Practice
March 29, 2007 - Wolf Greenfield Client Diomed Holdings Wins $12.5 Million Award in Patent Case - Jury Finds Two Defendants Infringed Patent for Varicose Vein Treatment
March 21, 2007 - Wolf Greenfield Names Oyer President and Managing Partner - Lawyer/Scientist Takes Reins at Boston Intellectual Property Law Firm
March 2007 - Can a Biological Sequence be Copyrighted?
January 9, 2007 - Supreme Court Rules in MedImmune Biotech Patent Case; Expert Lawyer Can Comment
January 2, 2007 - Supreme Court Throws Patent Owners a Curveball
November 2006 - Accelerated Examination of Patent Applications: Too Good To Be True?
June 23, 2006 - CLIENT ALERT — Supreme Court Dismisses Case Involving Patentability of Natural Phenomena
June 22, 2006 - Supreme Court Dismisses Case Involving Patentability of Natural Phenomena
Q&A Booklet - Q&A on Patents
Q&A Booklet - Q&A on Intellectual Property Litigation
Q&A Booklet - Q&A on Licensing and Transactions
